DE69826674D1 - Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend - Google Patents

Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend

Info

Publication number
DE69826674D1
DE69826674D1 DE69826674T DE69826674T DE69826674D1 DE 69826674 D1 DE69826674 D1 DE 69826674D1 DE 69826674 T DE69826674 T DE 69826674T DE 69826674 T DE69826674 T DE 69826674T DE 69826674 D1 DE69826674 D1 DE 69826674D1
Authority
DE
Germany
Prior art keywords
carnitin
alkanoyl
long
chain alkanols
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69826674T
Other languages
English (en)
Other versions
DE69826674T2 (de
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE69826674D1 publication Critical patent/DE69826674D1/de
Publication of DE69826674T2 publication Critical patent/DE69826674T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DE69826674T 1997-08-01 1998-07-09 Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend Expired - Lifetime DE69826674T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM970487 1997-08-01
IT97RM000487A IT1294227B1 (it) 1997-08-01 1997-08-01 Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
PCT/IT1998/000190 WO1999006039A1 (en) 1997-08-01 1998-07-09 Composition comprising l-carnitine or an alkanoyl l-carnitine and long-chain alkanols

Publications (2)

Publication Number Publication Date
DE69826674D1 true DE69826674D1 (de) 2004-11-04
DE69826674T2 DE69826674T2 (de) 2005-02-24

Family

ID=11405212

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69826674T Expired - Lifetime DE69826674T2 (de) 1997-08-01 1998-07-09 Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend

Country Status (16)

Country Link
US (1) US6328998B1 (de)
EP (1) EP0999832B1 (de)
JP (1) JP4295429B2 (de)
KR (1) KR100530878B1 (de)
AT (1) ATE277611T1 (de)
AU (1) AU741363B2 (de)
CA (1) CA2295746C (de)
DE (1) DE69826674T2 (de)
DK (1) DK0999832T3 (de)
ES (1) ES2229514T3 (de)
HK (1) HK1028547A1 (de)
IT (1) IT1294227B1 (de)
NZ (1) NZ501967A (de)
PT (1) PT999832E (de)
SI (1) SI0999832T1 (de)
WO (1) WO1999006039A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306178B1 (it) * 1999-07-27 2001-05-30 Sigma Tau Ind Farmaceuti Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento utile nel trattamento del paziente affetto da
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
US7214394B2 (en) * 2002-05-31 2007-05-08 Archer-Daniels-Midland Company Policosanol compositions, extraction from novel sources, and uses thereof
US20060166951A1 (en) * 2002-05-31 2006-07-27 Archer-Daniels-Midland Company Compositions and methods for sterol isolation and purification
CA2488498A1 (en) 2002-06-10 2003-12-18 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
AU2003240187A1 (en) * 2002-06-17 2003-12-31 Medestea Research And Production S.R.L. A process for preparing long chain saturated or unsaturated oxygenated compounds
US20090196914A1 (en) * 2002-11-14 2009-08-06 Optime Therapeutics, Inc. Liposomal l-carnitine
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US7615641B2 (en) * 2004-07-20 2009-11-10 Sino Pharmaceuticals Corporation Long chain aliphatic alcohol derivatives and methods of making and using same
US20070087975A1 (en) * 2005-10-17 2007-04-19 Sigma-Tau Industrie Farmaceutiche Riunite Spa Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP7266581B2 (ja) 2017-08-14 2023-04-28 アクセラ・ヘルス・インコーポレイテッド 肝疾患の治療のためのアミノ酸組成物
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) * 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
JPS6299323A (ja) * 1985-10-25 1987-05-08 Yoshihide Hagiwara 高脂血症剤
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
US5135956A (en) * 1988-10-18 1992-08-04 The Regents Of The University Of California Method of using cytoprotective alcohols to treat neural disease and neural injury
DE69026496D1 (de) * 1989-10-13 1996-05-15 Neurofit Analoge von vitamin a und ihre verwendung, insbesondere als cytotrophische und cytoprotective substanzen sowie diese substanzen enthaltende arzneimittel
JPH05103596A (ja) * 1991-10-11 1993-04-27 Yukio Yanagimoto 陸上動物用体力増強剤及び陸上動物用飼料
JPH05103629A (ja) * 1991-10-11 1993-04-27 Yukio Yanagimoto 体力増強剤
CU22229A1 (es) * 1992-09-29 1996-01-31 Dalmer Lab Sa Policosanol, una mezcla de alcoholes alifaticos primarios superiores para hipergregabilidad plaquetaria, los accidentes isquemicos, trombosis e incluso efectividad contra ulceras gastricas quimicamente inducidas y su proceso de obtencion de la caña de azucar. el tratamiento de complicaciones ateroscleroticas tales como la
JPH05310563A (ja) * 1992-05-15 1993-11-22 Nippon Oil & Fats Co Ltd カルシトニン産生増強剤
JPH0825891B2 (ja) * 1993-06-25 1996-03-13 株式会社薬理学中央研究所 脱脂米胚芽由来のリパーゼインヒビター
US5560928A (en) * 1995-06-23 1996-10-01 Defelice; Stephen L. Nutritional and/or dietary composition and method of using the same
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi

Also Published As

Publication number Publication date
WO1999006039A1 (en) 1999-02-11
IT1294227B1 (it) 1999-03-24
HK1028547A1 (en) 2001-02-23
DK0999832T3 (da) 2005-01-17
EP0999832B1 (de) 2004-09-29
NZ501967A (en) 2001-09-28
ATE277611T1 (de) 2004-10-15
JP4295429B2 (ja) 2009-07-15
KR20010022449A (ko) 2001-03-15
DE69826674T2 (de) 2005-02-24
JP2001511447A (ja) 2001-08-14
SI0999832T1 (en) 2004-12-31
AU8240798A (en) 1999-02-22
EP0999832A1 (de) 2000-05-17
ITRM970487A1 (it) 1999-02-01
US6328998B1 (en) 2001-12-11
CA2295746C (en) 2007-11-20
PT999832E (pt) 2004-12-31
ES2229514T3 (es) 2005-04-16
AU741363B2 (en) 2001-11-29
CA2295746A1 (en) 1999-02-11
KR100530878B1 (ko) 2005-11-23

Similar Documents

Publication Publication Date Title
DE69826674D1 (de) Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend
ZA9610769B (en) Pharmaceutical composition comprising l-carnitine or an alkanoyl l-carnitine in combination with a polyunsaturated fatty acid
ATE245978T1 (de) Zusammensetzungen enthaltend propionyl-l- carnitine und hydroxyzitronensäure oder pantothensäure
DK0773020T3 (da) Farmaceutiske præparater indeholdende L-carnitin eller derivater deraf i kombination med resveratrol eller derivater deraf til forebyggelsen og behandlingen af cardiovaskulære lidelser, perifere vaskulære sygdomme og perifer diabetisk neuropati
BG102733A (en) New substituted cyclic amino acids as pharmaceutical forms
CA2086429A1 (fr) Composition pharmaceutique ou cosmetique contenant en association un retinoide et un sterol
GEP20001898B (en) Method and Pharmaceutical Composition for Regulating Lipid Concentration with Mam
BR9810121A (pt) Utilização do acido petroselìnico nativo ou esterificado
BR9607565A (pt) Derivados de hidroxilamina úteis para produção de protetores moleculares e sua preparação
BG109876A (en) APPLICATION OF L-CARNITIN ESTERS OR ALCANAILIC L-CARNITINES AS CATIONARY LIPIDS FOR INTRACULAR TRANSMISSION OF PHARMACOLOGICALLY ACTIVE SUBSTANCES
DE59608698D1 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
PE20001325A1 (es) Combinacion de cerivastatina y fibratos
PT1023034E (pt) Formulacoes cosmeticas para prevencao e tratamento da queda de cabelo
PT795604E (pt) Estirpes de bacterias com metabolismo alterado de acidos biliares e sua utilizacao
PT998276E (pt) Utilizacao de derivados de alcanoil carnitina para o tratamento de disturbios de defice de atencao com hiperactividade
DE60002607D1 (de) Zusammensetzung zur vorbeugung und/oder behandlung von störungen aufgrund von abnormalen fettstoffmetabolismus, enthaltend l-carnitin und chitosan
DE60132374D1 (de) Alpha-ketoglutarate von wirkstoffen und deren zusammensetzungen
NZ298141A (en) Treating lipid metabolism disorder using TCF-II
BR9714785A (pt) Composições desinfetantes e processos de desinfecção de superfìcies
BR0007901A (pt) Método para a preservação ou redução deeventos cardiovasculares associados comintervenção coronária
AR009470A1 (es) COMPOSICIoN FARMACÉUTICA QUE CONTIENE CEPAS BACTERIANAS Y UTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON O CAUSADAS POR ALTERACIONES EN EL METABOLISMO DE LOS ÁCIDOS BILIARES, Y USO DE LAS MISMAS.
BR7700881U (pt) Papa pizza
GR1003099B (el) Ουσιες, φυσικης ή συνθετικης προελευσης, που ανηκουν στις ομαδες των τερπενοειδων, πολυφαινολων και προανθοκυανιδων, για χρηση στην προληψη και θεραπεια καθε τυπου υπερχοληστεριναιμιας και διαταραχης λιπιδιων, σε ανθρωπους και ζωα

Legal Events

Date Code Title Description
8364 No opposition during term of opposition